Format

Send to

Choose Destination
Am J Clin Exp Urol. 2018 Apr 1;6(2):62-77. eCollection 2018.

Androgen action in prostate function and disease.

Author information

1
Department of Biochemistry, Molecular and Cellular Biology, Georgetown University Medical CenterWashington, DC 20057, USA.
2
Laboratory of Genome Integrity, National Cancer Institute, National Institutes of HealthBethesda, Maryland 20892, USA.
3
Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public HealthBaltimore, Maryland 21205, USA.

Abstract

Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland that is frequently found in aging men. Androgens are essential for the development and differentiated function of the prostate, as well as for proliferation and survival of prostatic cells. In man, dog and rodent, there are age-related decreases in serum testosterone. Despite the lower serum testosterone levels, benign prostatic hyperplasia increases with age in men and dogs, while age-dependent prostatic hyperplasia develops in the dorsal and lateral lobes of the rat prostate. The possible mechanisms that lead to prostate hyperplasia have been extensively studied over many years. It is clear that androgens, estrogens and growth factors contribute to the condition, but the exact etiology remains unknown. Prostate cancer (CaP) represents a significant cause of death among males worldwide. As is the case of BPH, it is clear that androgens (testosterone and dihydrotestosterone) and their metabolites play important roles in the disease, but cause-effect relationships have not been established. Androgen deprivation therapy has been used for decades, primarily in the metastatic stage, to inhibit androgen-dependent prostate cancer cell growth. Androgen deprivation, which can be achieved by targeting hormone biosynthesis or androgen receptor activation, results in symptom amelioration. However, most patients will develop hormone refractory cancer or castration-resistant prostate cancer (CRPC). Prostatic epithelial cells demonstrate enormous plasticity in response to androgen ablation. This characteristic of prostatic epithelial cells may give rise to different populations of cells, some of which may not be dependent on androgen. Consequently, androgen receptor positive and negative cells might co-exist within CRPC. A clear understanding of this possible cellular heterogeneity and plasticity of prostate epithelial cells is necessary to develop an optimal strategy to treat or prevent CRPC.

KEYWORDS:

BPH; CRPC; Leydig cell; Prostate; aging; androgens

PMID:
29666834
PMCID:
PMC5902724

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center